Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
about
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis CAntiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and PrognosisElbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CParitaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise reviewPharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal ImpairmentAdvances in hepatitis C therapy: What is the current state - what come's next?Ribavirin: Past, present and futureStrategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesHepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant MedicineApproved Antiviral Drugs over the Past 50 YearsAnti-hepatitis C virus drugs and kidneyHepatitis C Therapy in Renal Patients: Who, How, When?Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseaseThe new era of hepatitis C virus therapyInterferon-free combination therapies for the treatment of hepatitis C: current insightsHepatitis C virus infection.Hepatitis C and kidney disease: A narrative review.Global epidemiology and burden of HCV infection and HCV-related disease.Recent advances in CKD and ESRD: A literature update.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysisHepatitis C in a New Era: A Review of Current TherapiesSofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience.Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.Elbasvir/Grazoprevir: First Global Approval.Direct-acting antivirals for chronic hepatitis C.Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionEfficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.[Are HVC patients on hemodialysis really difficult to treat patients?].Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIVSASLT guidelines: Update in treatment of Hepatitis C virus infection.Management of hepatitis C genotype 4 in the directly acting antivirals era.The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantationGrazoprevir/elbasvir combination therapy for HCV infection.The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
P2860
Q26740233-482222E3-8E97-45B3-A7F0-61D6A9C4D090Q26740313-07F6A2A0-DE2C-4393-B8D3-480466BF50F8Q26741123-8CC1350A-B24C-4B4A-8275-89608DE41A92Q26747705-905C7FEC-0BCF-401F-B569-47D404AB8755Q26751452-35751077-DE0B-4DB9-9DCC-03A09251D445Q26770036-82D9AD0B-FCCA-4C7D-8B70-EC29A4392BFEQ26775002-4863647F-3D2D-442D-B306-1C217FD07076Q26777086-23659948-9182-49AF-A43B-88CEAFA27E86Q26801198-B4A6A1ED-4210-4941-9905-7A0FFFD318BCQ27755387-F21BDFA3-A7EA-403D-8AFF-D7126DA15120Q28070279-737FB4D0-0DD6-4D91-9DA8-36B07B55947BQ28077130-7E1516A4-166B-4896-97F9-6DF48F407F9FQ28077263-90D68656-13B2-4FF8-A0A7-B737FAFE35E0Q28086947-2D49916B-A5BD-48B5-AD7E-C4208DE4E164Q28087400-CD713244-B63B-4914-935E-F0FD7E82AE89Q30235491-C04BED74-9B6F-451D-863A-C3AFE274A112Q30238652-E040A7D7-C70A-45EA-A97E-E664DC2C0F3BQ30240220-4F3CA2D6-D215-4EE7-A052-9458FD8EA99AQ30275339-8F40EBA2-58D5-4C80-9FC8-B3C4903B3F74Q31051529-96545E70-4D87-4CF6-BB73-836307B6545CQ33582596-011E72DD-122C-442F-8BBA-CC8C2B8E5F3CQ33585021-8E9B9B00-9CE4-4D3C-AC2D-E5FBBA292A68Q33621619-3C94CE1C-C0E2-47D7-84C7-C418C4C85BDAQ33845581-178AA4A4-4B60-45ED-B6EF-1FD0119DBAE5Q33878388-368760C9-41FE-478A-9DB5-0FC826ACEC36Q34516975-4E69B7F8-D9F5-4FE8-90CF-AF93C0B1D4E2Q34557595-AF2970DD-9AFC-4099-835A-E11B372FECC3Q36077546-4B3BDC6C-6BAE-4754-B2E7-7A47915DF1EAQ36220536-48DA25F6-0F7A-46E9-8F52-3CC736382B92Q36518540-C7EF26BF-97EE-4E8D-94D2-131F8F8CAB3AQ36519126-C400ACBC-ECF0-4882-B1FF-B4DBB09414E2Q36680222-24A12784-1965-4A40-A157-2AFBD44F4C32Q37055231-DEC10C0A-B3B4-4DFD-99B2-5F532B76F0ACQ37216507-C49DA162-AC25-4EAE-8D6F-A0A9D615786AQ37312151-74F574F1-E58F-4C1B-8BFA-A8BF886A834DQ37555313-CFB5C56B-88B7-44FD-91EE-AC01E2FAF368Q37563692-EC2C251F-02F0-4969-8DAD-E4E9F0511F7CQ37628539-842DD4B5-B71A-4285-A34F-A238788455E0Q37671965-8501443C-8894-4D76-981C-11E04E16C847Q37710140-4B3C53BD-9EA7-4219-A70F-9D54F033177D
P2860
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Grazoprevir plus elbasvir in t ...... : a combination phase 3 study.
@en
type
label
Grazoprevir plus elbasvir in t ...... : a combination phase 3 study.
@en
prefLabel
Grazoprevir plus elbasvir in t ...... : a combination phase 3 study.
@en
P2093
P1433
P1476
Grazoprevir plus elbasvir in t ...... : a combination phase 3 study.
@en
P2093
AnnMarie Liapakis
Annette Bruchfeld
Bach-Yen Nguyen
Beth Jackson
David R Nelson
David Roth
Eli Zuckerman
Eliav Barr
Howard Monsour
Janice Wahl
P304
P356
10.1016/S0140-6736(15)00349-9
P407
P577
2015-10-05T00:00:00Z